FDMT Q3 2021 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-81.6% YoY

Gross Profit

-$14M-1059.6% margin

Operating Income

-$23M-1658.9% margin

Net Income

-$22M-1628.0% margin

EPS (Diluted)

$-0.82

QoQ Revenue Growth

-90.6%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$18M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$241M

Total Liabilities

$16M

Stockholders' Equity

$224M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$7M	-81.6%
Gross Profit	-$14M	-$4M	-250.1%
Operating Income	-$23M	-$8M	-189.9%
Net Income	-$22M	-$8M	-183.9%

Geographic Segments

SWITZERLAND

$1M94%

NETHERLANDS

$64,0005%

UNITED STATES

$12,0001%